OBJECTIVE: To evaluate Ontario's provincial varicella vaccination program through analysis of aggregate varicella cases in order to determine whether there has been a decrease in reportable disease burden; and to assess varicella vaccine adverse events following immunization (AEFIs). METHODS: Aggregate varicella cases (1993-2013) were extracted from the reportable disease databases. Pre-program (1993-2004) and post-program (2007-2013) periods were chosen according to implementation of the publicly funded vaccination program. AEFIs following administration of varicella vaccines (2010-2013) were also extracted. Reporting rates were calculated using net doses distributed as the denominator. Serious AEFIs were defined using World Health Organization standards. RESULTS: The incidence of aggregate varicella reports decreased significantly over the study period (from 311.4 to 22.2 cases per 100,000 population in 1993 and 2013, respectively). Incidence also decreased significantly in all age groups between the pre- and the post-program periods with a shift in age distribution towards older individuals in the post-program period. A total of 162 AEFIs following varicella vaccine were reported between 2010 and 2013 for an annualized reporting rate of 14.6 per 100,000 doses distributed. The most common events were rash (37.3%), including eight reports of varicella-like rash (0.7 per 100,000 doses distributed). Ten serious events were reported (0.9 per 100,000 doses distributed), and all vaccine recipients recovered. CONCLUSION: Significant reductions in varicella disease incidence and low AEFI reporting rates were observed with the introduction of the publicly funded varicella vaccine program in Ontario. Continued surveillance is indicated to further assess trends in varicella disease and vaccine safety.
OBJECTIVE: To evaluate Ontario's provincial varicella vaccination program through analysis of aggregate varicella cases in order to determine whether there has been a decrease in reportable disease burden; and to assess varicella vaccine adverse events following immunization (AEFIs). METHODS: Aggregate varicella cases (1993-2013) were extracted from the reportable disease databases. Pre-program (1993-2004) and post-program (2007-2013) periods were chosen according to implementation of the publicly funded vaccination program. AEFIs following administration of varicella vaccines (2010-2013) were also extracted. Reporting rates were calculated using net doses distributed as the denominator. Serious AEFIs were defined using World Health Organization standards. RESULTS: The incidence of aggregate varicella reports decreased significantly over the study period (from 311.4 to 22.2 cases per 100,000 population in 1993 and 2013, respectively). Incidence also decreased significantly in all age groups between the pre- and the post-program periods with a shift in age distribution towards older individuals in the post-program period. A total of 162 AEFIs following varicella vaccine were reported between 2010 and 2013 for an annualized reporting rate of 14.6 per 100,000 doses distributed. The most common events were rash (37.3%), including eight reports of varicella-like rash (0.7 per 100,000 doses distributed). Ten serious events were reported (0.9 per 100,000 doses distributed), and all vaccine recipients recovered. CONCLUSION: Significant reductions in varicella disease incidence and low AEFI reporting rates were observed with the introduction of the publicly funded varicella vaccine program in Ontario. Continued surveillance is indicated to further assess trends in varicella disease and vaccine safety.
Authors: Gulam Khandaker; Helen Marshall; Elizabeth Peadon; Yvonne Zurynski; David Burgner; Jim Buttery; Michael Gold; Michael Nissen; Elizabeth J Elliott; Margaret Burgess; Robert Booy Journal: Arch Dis Child Date: 2011-02-24 Impact factor: 3.791
Authors: Roger Baxter; Paula Ray; Trung N Tran; Steve Black; Henry R Shinefield; Paul M Coplan; Edwin Lewis; Bruce Fireman; Patricia Saddier Journal: Pediatrics Date: 2013-04-01 Impact factor: 7.124
Authors: Meredith A Reynolds; Barbara M Watson; Kelly K Plott-Adams; Aisha O Jumaan; Karin Galil; Teresa J Maupin; John X Zhang; Jane F Seward Journal: J Infect Dis Date: 2008-03-01 Impact factor: 5.226
Authors: Dalya Guris; Aisha O Jumaan; Laurene Mascola; Barbara M Watson; John X Zhang; Sandra S Chaves; Paul Gargiullo; Dana Perella; Rachel Civen; Jane F Seward Journal: J Infect Dis Date: 2008-03-01 Impact factor: 5.226
Authors: Chi Yon Seo; Mohammed Rashid; Tara Harris; Jody Stapleton; Shelley L Deeks Journal: Paediatr Child Health Date: 2019-04-08 Impact factor: 2.253